Information Provided By:
Fly News Breaks for September 1, 2016
BSX
Sep 1, 2016 | 08:11 EDT
Argus analyst David Toung believes that Boston Scientific reported "strong" Q2 sales, while the company is gaining share. He thinks that the stock's valuation is attractive. Target $33.